#MSParis2017 – Promising Work in Pediatric and Secondary Progressive Patients Is Focus, Novartis Says in Interview
News
Gilenya (fingolimod) lowered relapse rates in children and adolescents with relapsing multiple sclerosis at a “magnitude” — almost 82 percent — never before seen in a ... Read more